Paul W. Noble, MD, received his Bachelor of Arts degree from Haverford College in Pennsylvania, and his medical degree from New York University School of Medicine. He completed his medical residency and chief residency at the University of California, San Francisco Hospitals. He completed his pulmonary and critical care fellowships at the University of Colorado and the National Jewish Center in Denver, Colorado.

From 1992–1997 Dr. Noble was Assistant Professor at Johns Hopkins School of Medicine, where he established the Interstitial Lung Disease Clinic. He moved to Yale University School of Medicine in 1997, where he became Professor of Medicine in 2004. He served as Director of the ILD Program at Yale-New Haven Hospital until 2006, when he moved to Duke University as the Chief of the Division of Pulmonary, Allergy and Critical Care Medicine. In January 2013, he moved to Cedars-Sinai Medical Center as Chair of the Department of Medicine.

Dr. Noble is a physician scientist with an active research laboratory focused on elucidating the basic mechanisms of lung fibrosis. His research laboratory has been funded by the National Institutes of Health since 1992. Dr. Noble has been involved in industry-sponsored clinical trials evaluating new therapies in IPF and participated in both the pirfenidone and nintedanib programs that led to the first FDA approved treatments for IPF. He continues to have an active clinical practice in ILD.

Dr. Noble is an elected member of the American Society of Clinical Investigation. He is also an elected council member of the Association of American Physicians.